Effectiveness of a Guided Web-Based Self-help Intervention to Prevent Depression in Patients With Persistent Back Pain: The PROD-BP Randomized Clinical Trial.

このレポートは 本レポートは によって検証されています。

この研究はインパクトが大きい可能性があると判断されました。 OEのAIによるハイインパクト指標は、論文が掲載されたジャーナルと論文自体の科学的内容の両方からのシグナルを統合することで、論文の影響力を推定します。 最先端の自然言語処理を用いて開発されたOEハイインパクトモデルは、ジャーナルのインパクトファクターのみよりも、研究の将来の引用実績をより正確に予測します。 これにより、臨床的に意義のある研究をより早く認識することができ、読者は将来の診療を形成する可能性が最も高い論文に焦点を当てることができます。

研究概要

Two hundred and ninety-five patients with persistent back pain and subclinical depression were randomized to receive standard treatment for back pain plus a web-based self-help intervention for depression (eSano BackCare-DP) or standard back pain treatment alone for the prevention of major depressive episodes (MDEs). The primary outcome of interest was the onset of a MDE within the 12 month follow-up period. Secondary outcomes of interest included clinician-rated depression severity (Hamilton Depression Rating Scale (HAM-D), Quick Inventory Depressive Symptomology (QIDS), and self-rated depression severity (PHQ-9). Additional outcomes included pain on a numeric rating scale (NRS), quality of life (Assessment of Quality of life [AQoL-6D]), pain related disability (Oswestry Disability Index [ODI]), pain self-efficacy (Pain Self-Efficacy Questionnaire [PSEQ]), work capacity (Subjective Prognostic Employment Scale [SPE]), and user satisfaction (Client Satisfaction with Online Interventions Questionnaire 8). Outcomes were assessed up to 12 months post-treatment. Results demonstrated that a statistically significantly lower incidence of depression onset was observed in the intervention group compared to the control group (p<0.001) at 12 months follow-up. Depression severity as measured by HAM-D, QIDS, PHQ-9 were all significantly in favour of the intervention group up to 12 months post-treatment. Moreover, ODI scores, PSEQ scores, and AQoL-6D scores were significantly in favour of the intervention group up to 12 months post-treatment. No significant differences in NRS pain scores and SPE scores, or the incidence of adverse events were observed between the two groups up to 12 months post-treatment.